Related Experiment Video
Updated: Sep 11, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Monitoring miR-29a for targeted therapy of cholangiocarcinoma based on a photoelectric sensor
Weiyuan Hao1, Cheng Chen2, Fei Cao1
1Department of Interventional Radiology, Zhejiang Key Laboratory of Imaging and Interventional Medicine, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, Zhejiang, China.
Abstract:
This study presents an integrated approach combining photoelectrochemical (PEC) biosensing, density functional theory (DFT), and machine learning (ML) to address diagnostic and mechanistic challenges in cholangiocarcinoma (CCA). A novel Bi4Ti3O12/WS2 heterojunction was engineered as a high-performance PEC platform, exhibiting broad-spectrum absorption extending to 850 nm and a 70% reduction in photoluminescence intensity due to suppressed electron-hole recombination. The optimized biosensor achieved ultrasensitive miR-29a detection with a linear range of 1 fM-200 nM, a detection limit of 0.19 fM, and 98.2-102.5% recovery in spiked serum, alongside robust specificity and reproducibility (1.3% RSD over 16 cycles). DFT calculations revealed interfacial electronic coupling between Bi4Ti3O12 and WS2, narrowing the bandgap to 1.571 eV and establishing a type-II charge transfer pathway, which synergistically enhanced photocurrent generation compared with pristine WS2. Parallel ML analysis of multi-omics datasets uncovered consistent miR-29a upregulation in CCA tumors and identified integrins COL4A1/CDK6 as top discriminative targets. The Random Forest classifier integrating miR-29a and targets achieved 0.890 AUC for tumor diagnosis, revealing pathway-specific regulatory networks. The bridging nanomaterial innovation with computational biology not only advances ultrasensitive miRNA detection but also deciphers miR-29a's dual role in CCA pathogenesis, offering a novel framework for precision oncology.

